Poor
Needs Revision
Patient Risk:
Moderate
Summary
The supplied Lipitor label does not address vitamin C or establish the interaction, safety, dose, adverse-effect, database, or research claims made. These claims are unsupported by the label, though none directly contradicts it.
Category Scores
Accurate Statements
Unsupported Statements
Lipitor (atorvastatin) has no established clinically significant interaction with vitamin C (ascorbic acid).
The label does not address vitamin C or establish that no clinically significant interaction exists.
Drug interaction databases report no direct pharmacokinetic or pharmacodynamic conflict between atorvastatin and vitamin C.
The label does not discuss interaction databases or atorvastatin–vitamin C pharmacokinetic or pharmacodynamic effects.
Vitamin C does not meaningfully affect atorvastatin metabolism via CYP3A4 or atorvastatin absorption.
The label discusses atorvastatin metabolism and absorption but does not address vitamin C.
Atorvastatin does not alter vitamin C levels.
The label does not discuss atorvastatin's effect on vitamin C levels.
Vitamin C is safe alongside statins at typical doses of up to 2,000 mg/day.
The label does not address vitamin C doses or its safety when taken with statins.
Research has explored potential antioxidant benefits of vitamin C in statin users to counter oxidative stress, with no interaction risks from those effects.
The label does not discuss vitamin C antioxidant research or associated interaction risks.
There are no case reports of issues in major pharmacovigilance databases such as FDA FAERS.
The label does not report a FAERS or other database search for vitamin C–atorvastatin cases.
At doses above 2,000 mg/day, vitamin C can cause gastrointestinal upset or kidney stones in susceptible people, and these risks are independent of Lipitor.
The label does not address high-dose vitamin C, these effects, or whether they are independent of Lipitor.
There is no evidence that vitamin C reduces statin efficacy or increases myopathy risk with statins.
The label does not address vitamin C's effects on statin efficacy or myopathy risk.
A 2019 review found no adverse interaction between statins and vitamin C, including in cardiovascular patients.
The label does not cite or describe this review or its findings.
Contradictions
Important Omissions
Clarify that the supplied Lipitor label does not address vitamin C, so the label alone cannot establish whether the combination is safe or whether an interaction exists.
Importance:
Major
Safety Assessment
Potential Patient Risk:
Moderate
The label does not substantiate the categorical assurances about combination safety or absence of interaction risk. It does not establish that those claims are false, but presenting them as label-supported could mislead.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
The response makes multiple vitamin C-specific interaction, safety, dose, database, and research claims that are not supported by the supplied label.
Suggested Improvement
State that the supplied label does not address vitamin C and avoid presenting its absence from the label as evidence that no interaction or risk exists.